Vistagen appoints Douglas J. Williamson, M.D. to Board of Directors

Vistagen Therapeutics, Inc.

Dr. Williamson appointed to Vistagen's Board effective July 29, 2026.
He received options to purchase 40,826 shares at $0.2433, vesting over three years.
Williamson brings 30 years of neuroscience drug development and regulatory experience.
He previously served as CMO of QurAlis, EVP R&D at Acadia, and senior roles at Lundbeck and Eli Lilly.
He will serve until the next annual meeting or until successor is elected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.